Mumps serological surveillance following 10 years of a one-dose mumps-containing-vaccine policy in Fujian Province, China

Mumps serological surveillance following 10 years of a one-dose mumps-containing-vaccine policy in Fujian Province, China

Background Since 2008, Fujian province provided measles-rubella (MR) vaccine at 8 months followed by measles-mumps-rubella (MMR) vaccine at 18 months a one-dose mumps-containing-vaccine (MuCV) schedule. Several mumps outbreaks have occurred recently in Fujian. Serological surveillance can assess pop...

Descrición completa

Detalles Bibliográficos
Main Authors:	Dong Li, Hairong Zhang, Na You, Zhifei Chen, Xiuhui Yang, Hangsu Zhang, Yong Zhou, Ningxuan Zheng, Weiyi Pan
Formato:	Artigo
Idioma:	English
Publicado:	Taylor & Francis Group 2022-11-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	mumps seroprevalence vaccination measles-mumps-rubella vaccine (mmr) geometric mean concentration (gmc)
Acceso en liña:	http://dx.doi.org/10.1080/21645515.2022.2096375

Títulos similares

Utility of serological screening for measles, mumps and rubella in immunocompromised patients
por: L Sticchi, et al.
Publicado: (2019-12-01)

Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina
por: Carla Vizzotti, et al.
Publicado: (2023-03-01)

Factors associated with mumps meningitis and the possible impact of vaccination
por: Kyuyol Rhie, et al.
Publicado: (2016-01-01)

Low Prevalence of Mumps IgG Antibodies among the Paediatric Population Attending Tertiary Care Hospital in Southern India- A Pilot Study
por: Aridass Dhanasezhian, et al.
Publicado: (2023-06-01)

Mumps Postexposure Prophylaxis with a Third Dose of Measles-Mumps-Rubella Vaccine, Orange County, New York, USA
por: Amy Parker Fiebelkorn, et al.
Publicado: (2013-09-01)

Emergent lineages of mumps virus suggest the need for a polyvalent vaccine
por: Meghan May, et al.
Publicado: (2018-01-01)

Mumps Vaccine Effectiveness Against Orchitis
por: Susan Hahné, et al.
Publicado: (2012-01-01)

Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin
por: Andrea A. Berry, et al.
Publicado: (2017-07-01)

Waning immunity of one-dose measles-mumps-rubella vaccine to mumps in children from kindergarten to early school age: a prospective study
por: Yuanbao Liu, et al.
Publicado: (2018-05-01)

High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China
por: Xiang Sun, et al.
Publicado: (2020-07-01)

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study
por: The MMR-162 Study Group
Publicado: (2018-12-01)

Measles, mumps and rubella vaccination coverage in capitals and interior region municipalities of Northeast Brazil: a household survey in a cohort of children born in 2017 and 2018
por: Adjoane Mauricio Silva Maciel, et al.
Publicado: (2024-12-01)

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines
por: Md Ahsan Habib, et al.
Publicado: (2023-01-01)

Effectiveness of an outbreak dose of mumps-containing vaccine in two First Nations communities in Northern Ontario, Canada
por: Wallis Rudnick, et al.
Publicado: (2022-01-01)

Antibody Levels at 3-Years Follow-Up of a Third Dose of Measles-Mumps-Rubella Vaccine in Young Adults
por: Patricia Kaaijk, et al.
Publicado: (2022-01-01)

Vaccine Effectiveness Estimates, 2004–2005 Mumps Outbreak, England
por: Cheryl Cohen, et al.
Publicado: (2007-01-01)

Mumps Outbreak among Highly Vaccinated Teenagers and Children in the Central Region of Portugal, 2012-2013
por: Eugénio Cordeiro, et al.
Publicado: (2015-08-01)

Raising Epidemiological Awareness: Assessment of Measles/MMR Susceptibility in Highly Vaccinated Clusters within the Hungarian and Croatian Population—A Sero-Surveillance Analysis
por: Dávid Szinger, et al.
Publicado: (2024-05-01)

Seroprevalence for Measles, Varicella, Mumps and Rubella in the Trainee Obstetric Population: A Survey in Southern Italy
por: Brunella Perfetto, et al.
Publicado: (2024-03-01)

Intralesional Injection of the Measles–Mumps–Rubella Vaccine into Resistant Palmoplantar Warts: A Randomized Controlled Trial
por: Mohammad Sadegh Rezai, et al.
Publicado: (2019-01-01)

Methicillin-resistant Staphylococcus Aureus Bacteraemia in a Young Boy following Mumps Infection: A Case Report
por: Jayakanthan Saravanan, et al.
Publicado: (2025-01-01)

Identification and description of mumps cases in a non-outbreak setting and evaluation of the effectiveness of mumps-containing vaccines over time
por: Ousseny Zerbo, et al.
Publicado: (2020-12-01)

Immune response to the mumps component of the MMR vaccine in the routine of immunisation services in the Brazilian National Immunisation Program
por: Eliane Matos dos Santos, et al.
Publicado: (2014-06-01)

One single-center serological survey on measles, rubella and mumps antibody levels of people in Youyang, China
por: Qing Wang, et al.
Publicado: (2021-11-01)

Loss of protective immunity of two-dose mumps-containing vaccine over time: concerns with the new strategy of the mumps immunization program in China
por: Danni Wang, et al.
Publicado: (2021-07-01)

Longitudinal Characterization of the Mumps-Specific HLA-A2 Restricted T-Cell Response after Mumps Virus Infection
por: Josien Lanfermeijer, et al.
Publicado: (2021-12-01)

Questionable Immunity to Mumps among Healthcare Workers in Italy—A Cross-Sectional Serological Study
por: Cristiana Ferrari, et al.
Publicado: (2024-05-01)

Seroepidemiology of Measles, Mumps and Rubella on Bonaire, St. Eustatius and Saba: The First Population-Based Serosurveillance Study in Caribbean Netherlands
por: Regnerus A. Vos, et al.
Publicado: (2019-10-01)

A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella
por: Manlio Fusciello, et al.
Publicado: (2022-06-01)

Domestic Tetravaccine (Measles-Rubella-Mumps) – Immunization of Premature Babies
por: V. V. Semerikov, et al.
Publicado: (2022-09-01)

Mumps vaccine effectiveness of a 3rd dose of measles, mumps, rubella vaccine in school settings during a mumps outbreak -- Arkansas, 2016-2017
por: Angela Guo, et al.
Publicado: (2023-12-01)

Two cases of measles after vaccination with measles mumps and rubella combined live attenuated vaccine
por: SHEN Jinhua, et al.
Publicado: (2022-05-01)

Determinants of Equity in Coverage of Measles-Containing Vaccines in Wales, UK, during the Elimination Era
por: Malorie Perry, et al.
Publicado: (2023-03-01)

The Combination Vaccine against Measles
por: M. P. Kostinov
Publicado: (2020-09-01)

The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study
por: Giuseppe La Torre, et al.
Publicado: (2017-08-01)

THE INFLUENCE OF DOUBLE IMMUNIZATION ON MORBIDITY OF MEASLES, MUMPS AND RUBELLA IN THE NORTH-WEST REGION OF RUSSIA
por: L. V. Lyalina, et al.
Publicado: (2014-07-01)

Epidemiological changes in mumps infections between 1990 and 2017 in urban area of Shanghai, China
por: Hong Pang, et al.
Publicado: (2021-05-01)

Will We Have a Cohort of Healthcare Workers Full Vaccinated against Measles, Mumps, and Rubella?
por: Andrea Trevisan, et al.
Publicado: (2020-02-01)

Assessing seropositivity of MMR antibodies in individuals aged 2–22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran’s National Measles Laboratory
por: Fateme Ghafoori, et al.
Publicado: (2024-07-01)

Efficacy of intralesional measles, mumps and rubella vaccine immunotherapy in Molluscum contagiosum: a prospective study
por: Fariz Sarshar, et al.
Publicado: (2023-01-01)